The influence of tifluadom on cholecystokinin-induced antinociception

Eur J Pharmacol. 1990 May 3;180(1):187-90. doi: 10.1016/0014-2999(90)90609-a.

Abstract

The effects of tifluadom, a benzodiazepine-kappa-opioid-receptor agonist, on cholecystokinin-octapeptide (CCK-8)-induced antinociception were investigated in the mouse writhing test. When given alone, tifluadom produced pronounced, dose-dependent analgesia. The antinociceptive effect of intracerebroventricularly injected CCK-8 was potentiated by high doses of tifluadom. In contrast, when tifluadom was applied at low doses which did not induce antinociception, the antinociceptive effect of CCK-8 was completely antagonized. It is concluded that tifluadom acts both as kappa-opioid receptor agonist and as an antagonist at CCK receptors mediating CCK-induced antinociception.

MeSH terms

  • Analgesics*
  • Animals
  • Benzodiazepines / pharmacology*
  • Cholecystokinin / antagonists & inhibitors
  • Cholecystokinin / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Injections, Intraventricular
  • Male
  • Mice
  • Mice, Inbred ICR
  • Morphine / pharmacology

Substances

  • Analgesics
  • Benzodiazepines
  • Morphine
  • Cholecystokinin
  • tifluadom